These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24713119)

  • 1. Inhibition of hepatitis C virus infection by NS5A-specific aptamer.
    Yu X; Gao Y; Xue B; Wang X; Yang D; Qin Y; Yu R; Liu N; Xu L; Fang X; Zhu H
    Antiviral Res; 2014 Jun; 106():116-24. PubMed ID: 24713119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein.
    Gao Y; Yu X; Xue B; Zhou F; Wang X; Yang D; Liu N; Xu L; Fang X; Zhu H
    PLoS One; 2014; 9(2):e90333. PubMed ID: 24587329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of hepatitis C virus production by aptamers against the core protein.
    Shi S; Yu X; Gao Y; Xue B; Wu X; Wang X; Yang D; Zhu H
    J Virol; 2014 Feb; 88(4):1990-9. PubMed ID: 24307579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of hepatitis C virus infection by DNA aptamer against envelope protein.
    Yang D; Meng X; Yu Q; Xu L; Long Y; Liu B; Fang X; Zhu H
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4937-44. PubMed ID: 23877701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase.
    Lee CH; Lee YJ; Kim JH; Lim JH; Kim JH; Han W; Lee SH; Noh GJ; Lee SW
    J Virol; 2013 Jun; 87(12):7064-74. PubMed ID: 23596299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.
    McGivern DR; Masaki T; Williford S; Ingravallo P; Feng Z; Lahser F; Asante-Appiah E; Neddermann P; De Francesco R; Howe AY; Lemon SM
    Gastroenterology; 2014 Aug; 147(2):453-62.e7. PubMed ID: 24768676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells.
    Bellecave P; Cazenave C; Rumi J; Staedel C; Cosnefroy O; Andreola ML; Ventura M; Tarrago-Litvak L; Astier-Gin T
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2097-110. PubMed ID: 18347106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
    Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel HCV replication inhibitors.
    McGowan DC; Khamlichi MD; De Groot A; Pauwels F; Delouvroy F; Van Emelen K; Simmen K; Raboisson P
    Mol Divers; 2017 May; 21(2):475-481. PubMed ID: 28293834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
    Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
    Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.
    Tellinghuisen TL; Foss KL; Treadaway J
    PLoS Pathog; 2008 Mar; 4(3):e1000032. PubMed ID: 18369478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
    Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NS5A inhibitors for the treatment of hepatitis C infection.
    Gitto S; Gamal N; Andreone P
    J Viral Hepat; 2017 Mar; 24(3):180-186. PubMed ID: 27925362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.